secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2026-08-12T20:07:49+00:00
Accession:  0001055726-26-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO reports Q2 2026 net loss of $6.0M; INO-3107 PDUFA on Oct 30, 2026
------------------------------------------------------------------------

- Net loss of $6.0M ($0.07/share) vs $23.5M ($0.61) in Q2 2025; includes $13.9M non-cash warrant gain.
- Cash and investments $36.7M at June 30, 2026, plus $18.3M from July offering; runway into late Q1 2027.
- FDA review of INO-3107 BLA continues; PDUFA target action date October 30, 2026; commercial launch prep ongoing.
- ApolloBio reported positive Phase 3 topline for VGX-3100 in China for cervical dysplasia.
- Operating expenses fell to $18.6M from $23.1M YoY; R&D down to $10.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/0001055726-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001055726-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer